Clearmind Medicine to Execute 1-for-10 Reverse Share Split May 21
Clearmind Medicine will implement a 1-for-10 reverse share split effective May 21, reducing its issued and outstanding common shares from 10,190,337 to approximately 1,019,033. The action, approved March 18, adjusts options and warrants proportionately and aims to restore compliance with Nasdaq’s Minimum Bid Price Rule.
1. Reverse Split Details
Clearmind Medicine’s board approved a 1-for-10 reverse share split on March 18, 2026, to take effect May 21. The split will convert every ten issued and outstanding common shares into one new common share, with fractional shares rounded up to the nearest whole share.
2. Impact on Share Count and Securities
Following the reverse split, issued and outstanding common shares will drop from 10,190,337 to about 1,019,033. The per-share exercise price and number of shares issuable under all outstanding options and warrants will be proportionately adjusted to reflect the new share count.
3. Nasdaq Compliance Objective
The reverse split is designed to raise the per-share trading price and bring Clearmind back into compliance with Nasdaq’s Minimum Bid Price Rule. The company’s authorized share capital remains unchanged and unlimited following the adjustment.